Rifaximin-containing pharmaceutical preparation

A technology of rifaximin and rifaximin, which is applied in the field of rifaximin-containing pharmaceutical preparations for the treatment of intestinal infections and its preparation, and can solve the problems that tablets are unfavorable for children to take, inconvenient to take outside, and unfavorable for children to take, etc. , to achieve the effect of reducing the fear of taking medicine, improving bioavailability and good taste

Active Publication Date: 2015-01-14
黑龙江童医生儿童生物制药有限公司
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] For tablets, when the dose for children is less than one tablet, artificial division is required, resulting in inaccurate dosage. Some coated tablets lose their specific functions such as protection, taste masking, controlled release, and isolation after artificial division. Dosage is not suitable for children to take, difficulty swallowing
[0008] For capsules, when children use less than one capsule, the method of pouring out the medicine in the capsule and taking it with water is often adopted. Capsules are generally large, which is even more unfavorable for children to take.
[0009] For dry suspension, if the dosage for children is less than the minimum packaging volume, it needs to be manually disassembled, resulting in inaccurate dosage. When taking it, it needs to be mixed with water, which is inconvenient to take outside.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rifaximin-containing pharmaceutical preparation
  • Rifaximin-containing pharmaceutical preparation
  • Rifaximin-containing pharmaceutical preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] A rifaximin gel, measured in 1000ml, consists of the following components:

[0057]

[0058] The preparation method is to add aspartame and calcium chloride to an appropriate amount of purified water to dissolve; add konjac gum and carrageenan, add purified water to 80% of the total amount, heat and stir until the sol is boiled; when the above gel is cooled to 60 ° C , add the prescribed amount of rifaximin dispersed with purified water and orange essence, potassium sorbate and citric acid dissolved in an appropriate amount of purified water, add water to the full amount, and stir well; filter while it is hot, and take the filtered liquid colloid for Subpackage, that is.

Embodiment 2

[0060] A rifaximin gel, measured in 1000ml, consists of the following components:

[0061]

[0062]

[0063] The preparation method is to dissolve steviol glycoside and potassium chloride in appropriate amount of water respectively; add carrageenan, add purified water to 80% of the total amount, heat and stir until the sol is boiled; when the above gel is cooled to 60°C, add purified water to disperse A good prescription amount of rifaximin and ethyl p-hydroxybenzoate, pineapple essence, sodium dihydrogen phosphate and disodium hydrogen phosphate dissolved in an appropriate amount of purified water, add water to the full amount, stir well, filter while hot, and take the filtered The liquid colloid is subpackaged, and it is obtained.

Embodiment 3

[0065] A rifaximin gel, measured in 1000ml, consists of the following components:

[0066]

[0067]

[0068] Preparation method: add sucrose and calcium chloride to appropriate amount of water to dissolve respectively; add agar, add purified water to 80% of the total amount, heat and stir until the sol is boiled; when the above gel is cooled to 60°C, add purified water dispersed The prescribed amount of rifaximin, sorbic acid, apple essence, citric acid, and sodium citrate dissolved in an appropriate amount of purified water, add water to the full amount, stir well, filter while it is hot, and take the filtered liquid colloid for sub-packaging to obtain .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical preparation containing rifaximin gel and rifaximin oral emulsion and a preparation method thereof, wherein the gel comprises rifaximin and a gel matrix, the mass ratio of the rifaximin to the gel matrix is (2-80):(5-64), and the gel matrix comprises 2-30 parts by weight of a water-soluble gel matrix and 0.5-2 parts by weight of a modifier; and the rifaximin oral emulsion comprises 1-40 parts by weight of rifaximin, 50-350 parts by weight of an oil phase, 1-300 parts by weight of an emulsifier, and 0-150 parts by weight of a co-emulsifier. In the preparation, on the premise of guaranteeing that the dose of a main drug is appropriate, through the selection of auxiliary materials and preparation methods, rifaximin is prepared into gel or oral emulsion, thereby facilitating the oral administration and absorption of drugs, and achieving relatively high bioavailability. Meanwhile, a newer and better dosage form choice is provided for clinic.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to a pharmaceutical preparation containing rifaximin for treating intestinal infection and a preparation method thereof. Background technique [0002] Diarrhea is a common symptom that seriously threatens human health. It is considered to be one of the five common clinical symptoms and one of the top five killers of children. According to the WHO survey, 1.2 billion children under the age of five are infected with diarrhea every year, and 4,000,000 children die from diarrhea, especially in developing countries. Diarrhea is not only quite common among children under the age of 5, but also an important cause of death. In developed countries, each person suffers from 1-3 diarrheal diseases per year on average, and children in poor areas of tropical developing countries suffer from 5-18 diarrheal diseases per person per year on average, especially infectious diarrhea. In my c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K9/107A61K31/439A61P1/12A61P31/04
Inventor 王娜姜波刘晓磊
Owner 黑龙江童医生儿童生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products